Striptan 50mg Tablets

البلد: ماليزيا

اللغة: الإنجليزية

المصدر: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

العنصر النشط:

SUMATRIPTAN SUCCINATE

متاح من:

JETPHARMA SDN. BHD.

INN (الاسم الدولي):

SUMATRIPTAN SUCCINATE

الوحدات في الحزمة:

6Tablet Tablets

المصنعة من قبل:

INTAS PHARM LTD

خصائص المنتج

For the use of a Registered Medical Practitioner or a Hospital or a
Laboratory only.
STRIPTAN 50 & STRIPTAN 100
(SUMATRIPTAN SUCCINATE TABLETS 50 MG &100 MG)
NAME OF PRODUCT
STRIPTAN 50 (Sumatriptan Succinate Tablets 50 mg)
STRIPTAN 100 (Sumatriptan Succinate Tablets 100 mg)
NAME AND STRENGTH OF ACTIVE INGREDIENT
Sumatriptan Succinate Ph. Eur. eq. to Sumatriptan 50 mg
Sumatriptan Succinate Ph. Eur. eq. to Sumatriptan 100 mg
DOSAGE FORM
Film Coated Tablet
PRODUCT DESCRIPTION
SUMATRIPTAN
SUCCINATE
TABLETS
50
MG:
Pink
colored,
capsule
shaped
biconvex, film coated tablet plain on both sides.
SUMATRIPTAN SUCCINATE TABLETS 100 MG: White to off-white, capsule
shaped
biconvex, film coated tablet plain on both sides.
PHARMACODYNAMICS & PHARMACOKINETICS
PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Analgesics: Selective 5-HT1 receptor
agonists.
ATC code: N02CC01
Sumatriptan has been demonstrated to be a specific and selective
5-Hydroxy-
tryptamine1 (5HT1D) receptor agonist with no effect on other 5HT
receptor
(5-HT2-5-HT7)
subtypes.
The
vascular
5-HT1D
receptor
is
found
predominantly in cranial blood vessels and mediates vasoconstriction.
In
animals, sumatriptan selectively constricts the carotid arterial
circulation but
does not alter cerebral blood flow. The carotid arterial circulation
supplies
blood to the extracranial and intracranial tissues such as the
meninges and
dilatation of and/or oedema formation in these vessels is thought to
be the
underlying mechanism of migraine in man.
In addition, evidence from animal studies suggests that sumatriptan
inhibits
trigeminal nerve activity. Both these actions (cranial
vasoconstriction and
inhibition of trigeminal nerve activity) may contribute to the
anti-migraine
action of sumatriptan in humans.
Sumatriptan remains effective in treating menstrual migraine i.e.
migraine
without aura that occurs between 3 days prior and up to 5 days post
onset of
menstruation. Sumatriptan should be taken as soon as possible in an
attack.
Clinical response begins around 30 minutes foll